$PRCT
PROCEPT BioRobotics Corp Stock $prct

$prct Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000162828022006885 Filed on March 22, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$10.14M	$34.47M	$7.717M
YoY Change	31.37%	346.72%
Cost Of Revenue	$5.622M	$18.61M	$8.972M
YoY Change	-37.34%	107.4%
Gross Profit	$4.516M	$15.87M	-$1.255M
YoY Change	-459.84%	-1364.14%
Gross Profit Margin	44.55%	46.02%	-16.26%
Selling, General & Admin	$16.27M	$51.04M	$30.27M
YoY Change	-46.25%	68.59%
% of Gross Profit	360.3%	321.69%
Research & Development	$5.076M	$18.99M	$16.27M
YoY Change	-68.81%	16.7%
% of Gross Profit	112.4%	119.72%
Depreciation & Amortization	$763.0K	$3.324M	$715.0K
YoY Change	6.71%	16.22%
% of Gross Profit	16.9%	20.95%
Operating Expenses	$21.35M	$70.03M	$46.55M
YoY Change	-54.14%	50.45%
Operating Profit	-$16.83M	-$54.16M	-$47.80M
YoY Change	-64.79%	13.31%
Interest Expense	-$1.503M	$5.810M	-$5.402M
YoY Change	-72.18%	10.44%
% of Operating Profit
Other Income/Expense, Net	-$14.00K	-$154.0K	$185.0K
YoY Change	-107.57%	516.0%
Pretax Income	-$18.35M	-$59.85M	-$53.02M
YoY Change	-65.39%	12.89%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$18.35M	-$59.85M	-$53.02M
YoY Change	-65.39%	12.89%
Net Earnings / Revenue	-180.98%	-173.62%	-687.04%
Basic Earnings Per Share		-$3.63
Diluted Earnings Per Share	-$414.3K	-$3.63	-$1.254M
COMMON SHARES
Basic Shares Outstanding	43.50M shares	16.48M shares
Diluted Shares Outstanding		16.48M shares

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$304.3M	$304.3M
YoY Change		203.92%
Cash & Equivalents	$304.3M	$290.7M	$100.1M
Short-Term Investments
Other Short-Term Assets	$3.412M	$3.412M
YoY Change		210.18%
Inventory	$13.15M	$13.98M	$6.924M
Prepaid Expenses
Receivables	$4.464M	$4.464M	$1.549M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$326.2M	$326.2M	$110.3M
YoY Change	195.83%	195.83%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.045M	$8.324M	$8.274M
YoY Change	-39.03%	-35.55%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$777.0K
YoY Change		0.0%
Total Long-Term Assets	$10.85M	$10.85M	$15.72M
YoY Change	-30.95%	-30.95%
TOTAL ASSETS
Total Short-Term Assets	$326.2M	$326.2M	$110.3M
Total Long-Term Assets	$10.85M	$10.85M	$15.72M
Total Assets	$337.0M	$337.0M	$126.0M
YoY Change	167.54%	167.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.029M	$2.029M	$1.240M
YoY Change	63.63%	63.63%
Accrued Expenses	$11.21M	$11.21M
YoY Change		43.21%
Deferred Revenue	$1.025M		$233.0K
YoY Change	339.91%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$4.551M
YoY Change	-100.0%	-100.0%
Total Short-Term Liabilities	$16.24M	$16.24M	$14.53M
YoY Change	11.81%	11.81%
LONG-TERM LIABILITIES
Long-Term Debt	$50.00M	$50.00M	$44.41M
YoY Change	12.6%	12.6%
Other Long-Term Liabilities	$200.0K	$3.687M	$200.0K
YoY Change	0.0%	-39.34%
Total Long-Term Liabilities	$50.20M	$53.69M	$44.61M
YoY Change	12.55%	6.35%
TOTAL LIABILITIES
Total Short-Term Liabilities	$16.24M	$16.24M	$14.53M
Total Long-Term Liabilities	$50.20M	$53.69M	$44.61M
Total Liabilities	$69.93M	$69.93M	$65.01M
YoY Change	7.57%	7.57%
SHAREHOLDERS EQUITY
Retained Earnings	-$261.5M		-$201.7M
YoY Change	29.68%
Common Stock	$0.00		$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$267.1M	$267.1M	-$182.9M
YoY Change
Total Liabilities & Shareholders Equity	$337.0M	$337.0M	$126.0M
YoY Change	167.54%	167.54%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$18.35M	-$59.85M	-$53.02M
YoY Change	-65.39%	12.89%
Depreciation, Depletion And Amortization	$763.0K	$3.324M	$715.0K
YoY Change	6.71%	16.22%
Cash From Operating Activities	-$16.48M	-$57.33M	-$13.45M
YoY Change	22.54%	18.6%
INVESTING ACTIVITIES
Capital Expenditures	-$332.0K	$592.0K	-$9.000K
YoY Change	3588.89%	154.08%
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change
Cash From Investing Activities	-$332.0K	-$592.0K	-$9.000K
YoY Change	3588.89%	154.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$0.00
YoY Change
Cash From Financing Activities	644.0K	$262.1M	237.0K
YoY Change	171.73%	145.49%
NET CHANGE
Cash From Operating Activities	-16.48M	-$57.33M	-13.45M
Cash From Investing Activities	-332.0K	-$592.0K	-9.000K
Cash From Financing Activities	644.0K	$262.1M	237.0K
Net Change In Cash	-16.16M	$204.2M	-13.22M
YoY Change	22.3%	250.87%
FREE CASH FLOW
Cash From Operating Activities	-$16.48M	-$57.33M	-$13.45M
Capital Expenditures	-$332.0K	$592.0K	-$9.000K
Free Cash Flow	-$16.14M	-$57.93M	-$13.44M
YoY Change	20.15%	19.25%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020Q2	dei	Entity Public Float EntityPublicFloat	0	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	43988574	shares
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001588978
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.2105
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-04321
CY2021	dei	Entity Registrant Name EntityRegistrantName	PROCEPT BIOROBOTICS CORPORATION
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-0199180
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	900 Island Drive
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Redwood City
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94065
CY2021	dei	City Area Code CityAreaCode	(650)
CY2021	dei	Local Phone Number LocalPhoneNumber	232-7200
CY2021	dei	Security12b Title Security12bTitle	Common stock, $0.00001 par value per share
CY2021	dei	Trading Symbol TradingSymbol	PRCT
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2020Q4	us-gaap	Inventory Net InventoryNet	6924000	USD
CY2021	dei	Auditor Firm AuditorFirmId	238
CY2021	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2021	dei	Auditor Location AuditorLocation	San Jose, California
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	304320000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	100130000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4464000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1549000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	13147000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4242000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1653000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	326173000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	110256000	USD
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	777000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	777000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5045000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8274000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3279000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4641000	USD
CY2021Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	1750000	USD
CY2020Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	2023000	USD
CY2021Q4	us-gaap	Assets Assets	337024000	USD
CY2020Q4	us-gaap	Assets Assets	125971000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2029000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1240000	USD
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	6475000	USD
CY2020Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	4640000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1025000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	233000	USD
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	4551000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2105000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1708000	USD
CY2021Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0	USD
CY2020Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	177000	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	4608000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1977000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16242000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14526000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	50004000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	44407000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1991000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4096000	USD
CY2021Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1496000	USD
CY2020Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1782000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	200000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	200000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7717000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	69933000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	65011000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	0	shares
CY2020Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	26984000	shares
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2021Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	25402000	shares
CY2020Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	25402000	shares
CY2021Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	0	USD
CY2020Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	245768000	USD
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	243854000	USD
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	528666000	USD
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	267091000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-182894000	USD
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	40000000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43676000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43676000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4713000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4713000	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	18788000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-54000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-14000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-261521000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-201668000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	337024000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	125971000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	34473000	USD
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	18608000	USD
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	8972000	USD
CY2021	us-gaap	Gross Profit GrossProfit	15865000	USD
CY2020	us-gaap	Gross Profit GrossProfit	-1255000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18993000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16275000	USD
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	51036000	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	30272000	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	70029000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	46547000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-54164000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-47802000	USD
CY2021	us-gaap	Interest Expense InterestExpense	5810000	USD
CY2020	us-gaap	Interest Expense InterestExpense	5261000	USD
CY2021	prct	Interest And Other Income Expense InterestAndOtherIncomeExpense	121000	USD
CY2020	prct	Interest And Other Income Expense InterestAndOtherIncomeExpense	44000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-59853000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-53019000	USD
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.63
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.63
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-14.47
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-14.47
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16480000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16480000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3663000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3663000	shares
CY2021	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-40000	USD
CY2020	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-18000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-59893000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-53037000	USD
CY2019Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	20998000	shares
CY2019Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	173068000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-18000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-182894000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-143837000	USD
CY2020	prct	Temporary Equity Shares Conversion Of Convertible Securities TemporaryEquitySharesConversionOfConvertibleSecurities	1474000	shares
CY2020	prct	Temporary Equity Amount Conversion Of Convertible Securities TemporaryEquityAmountConversionOfConvertibleSecurities	9520000	USD
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	9520000	USD
CY2020	prct	Temporary Equity Stock Issued During Period Shares Warrant Exercises TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises	651000	shares
CY2020	prct	Temporary Equity Stock Issued During Period Value Warrant Exercises TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises	3818000	USD
CY2020	prct	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	11000	USD
CY2020Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	496000	USD
CY2020	prct	Temporary Equity Stock Issued During Period Shares New Issues TemporaryEquityStockIssuedDuringPeriodSharesNewIssues	5227000	shares
CY2020	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	76488000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2276000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition	2173000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-53019000	USD
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	25402000	shares
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	243854000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	267091000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-59853000	USD
CY2021Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	290000	USD
CY2021	prct	Temporary Equity Stock Issued During Period Shares New Issues TemporaryEquityStockIssuedDuringPeriodSharesNewIssues	4448000	shares
CY2021	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	84710000	USD
CY2021	prct	Temporary Equity Stock Issued During Period Shares Warrant Exercises TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises	62000	shares
CY2021	prct	Temporary Equity Stock Issued During Period Value Warrant Exercises TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises	970000	USD
CY2021	prct	Temporary Equity Shares Conversion Of Convertible Securities TemporaryEquitySharesConversionOfConvertibleSecurities	29912000	shares
CY2021	prct	Temporary Equity Amount Conversion Of Convertible Securities TemporaryEquityAmountConversionOfConvertibleSecurities	329534000	USD
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	329534000	USD
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	16121000	USD
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	172364000	USD
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4184000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition	3796000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-40000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-59853000	USD
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2020	us-gaap	Other Noncash Expense OtherNoncashExpense	60000	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2914000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-53019000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3324000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2860000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	3796000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	2173000	USD
CY2021	prct	Fair Value Adjustment Of Warrants And Gain Loss On Derivative Instruments Net Pretax FairValueAdjustmentOfWarrantsAndGainLossOnDerivativeInstrumentsNetPretax	-199000	USD
CY2020	prct	Fair Value Adjustment Of Warrants And Gain Loss On Derivative Instruments Net Pretax FairValueAdjustmentOfWarrantsAndGainLossOnDerivativeInstrumentsNetPretax	114000	USD
CY2021	prct	Non Cash Lease Accretion Expense NonCashLeaseAccretionExpense	345000	USD
CY2020	prct	Non Cash Lease Accretion Expense NonCashLeaseAccretionExpense	157000	USD
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	650000	USD
CY2020	us-gaap	Inventory Write Down InventoryWriteDown	109000	USD
CY2021	us-gaap	Other Noncash Expense OtherNoncashExpense	0	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	511000	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6124000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3105000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2631000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	339000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	812000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-205000	USD
CY2021	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	1834000	USD
CY2020	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	2302000	USD
CY2021	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	1045000	USD
CY2020	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	1049000	USD
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	792000	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	127000	USD
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	2479000	USD
CY2020	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	199000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-57334000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-48343000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	592000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	233000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-592000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-233000	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4184000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2288000	USD
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	172364000	USD
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2021	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	0	USD
CY2020	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	24685000	USD
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	858000	USD
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3310000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	262116000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	106771000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	204190000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	58195000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	100907000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	42712000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	305097000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	100907000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	304320000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	100130000	USD
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	777000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	777000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	305097000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	100907000	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	4750000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	3969000	USD
CY2021	prct	Transfer From Inventory To Property And Equipment Net TransferFromInventoryToPropertyAndEquipmentNet	-679000	USD
CY2020	prct	Transfer From Inventory To Property And Equipment Net TransferFromInventoryToPropertyAndEquipmentNet	2822000	USD
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	210000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	210000	USD
CY2021	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	329534000	USD
CY2021Q3	us-gaap	Payments For Underwriting Expense PaymentsForUnderwritingExpense	13200000	USD
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	304300000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-261500000	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	Use of EstimatesThe preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the consolidated financial statements. Management uses significant judgment when making estimates related to its common stock valuation in periods before the Company’s IPO and related stock-based compensation expense, right-of-use lease asset, lease liability, the valuations of the redeemable convertible preferred stock warrant liability and loan facility derivative liability, as well as certain accrued liabilities. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates.
CY2021Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2900000	USD
CY2021Q3	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	29912264	shares
CY2021Q3	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	29912264	shares
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents and, to a lesser extent, accounts receivable. The Company believes that credit risk in its accounts receivable is mitigated by its credit evaluation process, relatively short collection terms and diversity of its customer base. The Company generally does not require collateral and losses on accounts receivable have historically been within management’s expectations. </span></div>The Company’s investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies, and institutions with investment-grade credit ratings, as well as corporate debt or commercial paper issued by the highest quality financial and non-financial companies, and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash and cash equivalents and issuers of investments to the extent recorded on the balance sheets. The Company has limited its credit risk associated with cash and cash equivalents by placing its investments with banks it believes are highly creditworthy and with highly rated investments.
CY2021	us-gaap	Property Plant And Equipment Impairment PropertyPlantAndEquipmentImpairment	Impairment of Long-Lived Assets Long-lived assets consist primarily of property and equipment and intangible assets, net, and are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require that a long-lived asset be tested for possible impairment, the Company compares the undiscounted cash flows expected to be generated by the asset group to the carrying amount of the asset group. If the carrying amount of the long-lived asset is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying amount exceeds its fair value. The Company determines fair value using the income approach based on the present value of expected future cash flows or other appropriate measures of estimated fair value. The Company’s cash flow assumptions consider historical and forecasted revenue and operating costs and other relevant factors. During the years ended December 31, 2021 and 2020, the Company has not recorded impairment charges on its long-lived assets.
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2020Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0	USD
CY2021Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0	USD
CY2021Q3	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	29912264	shares
CY2021Q3	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	29912264	shares
CY2021	prct	Product Warranty Term ProductWarrantyTerm	P1Y
CY2021	prct	Product Warranty Term ProductWarrantyTerm	P1Y
CY2021	prct	Service Agreement Amortization Period ServiceAgreementAmortizationPeriod	P1Y
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3663000	shares
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-14.47
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	34473000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7717000	USD
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-14.47
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3663000	shares
CY2021Q3	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	29912264	shares
CY2021Q3	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	29912264	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16480000	shares
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-59853000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-53019000	USD
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16480000	shares
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.63
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.63
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6593000	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	31981000	shares
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	6740000	USD
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2647000	USD
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	905000	USD
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	51000	USD
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	5502000	USD
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4226000	USD
CY2020Q4	prct	Prepaid Software PrepaidSoftware	375000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	13147000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	6924000	USD
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	2333000	USD
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	124000	USD
CY2021Q4	prct	Prepaid Inventory PrepaidInventory	830000	USD
CY2020Q4	prct	Prepaid Inventory PrepaidInventory	553000	USD
CY2021Q4	prct	Prepaid Software PrepaidSoftware	428000	USD
CY2021Q4	us-gaap	Prepaid Rent PrepaidRent	253000	USD
CY2020Q4	us-gaap	Prepaid Rent PrepaidRent	245000	USD
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	398000	USD
CY2020Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	356000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4242000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1653000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11739000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13062000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6694000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4788000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5045000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8274000	USD
CY2021Q4	prct	Accrued Purchases AccruedPurchases	1105000	USD
CY2020Q4	prct	Accrued Purchases AccruedPurchases	432000	USD
CY2021Q4	prct	Contract With Customer Deposit Liability Current ContractWithCustomerDepositLiabilityCurrent	741000	USD
CY2020Q4	prct	Accrued Travel Expenses Current AccruedTravelExpensesCurrent	138000	USD
CY2020Q4	prct	Contract With Customer Deposit Liability Current ContractWithCustomerDepositLiabilityCurrent	0	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	600000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	339000	USD
CY2021Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	515000	USD
CY2020Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	302000	USD
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	405000	USD
CY2020Q4	us-gaap	Interest Payable Current InterestPayableCurrent	403000	USD
CY2021Q4	prct	Accrued Travel Expenses Current AccruedTravelExpensesCurrent	281000	USD
CY2021Q4	prct	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	183000	USD
CY2020Q4	prct	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	47000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	778000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	316000	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	4608000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1977000	USD
CY2019Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2500000	USD
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	76000	USD
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	184000	USD
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-64000	USD
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-185000	USD
CY2021	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	135000	USD
CY2020	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-300000	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-154000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-25000	USD
CY2021	prct	Interest And Other Income Expense InterestAndOtherIncomeExpense	121000	USD
CY2020	prct	Interest And Other Income Expense InterestAndOtherIncomeExpense	44000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	800000	USD
CY2021Q4	prct	Finite Lived Intangible Assets Amortization Expense Expected Annual Rate Per Year FiniteLivedIntangibleAssetsAmortizationExpenseExpectedAnnualRatePerYear	300000	USD
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	300000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	300000	USD
CY2021	prct	Line Of Credit Facility Gain Loss On Amendment Of Debt Terms LineOfCreditFacilityGainLossOnAmendmentOfDebtTerms	0	USD
CY2020Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	26983984	shares
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	25402402	shares
CY2020Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	25402402	shares
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	243854000	USD
CY2021Q3	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	29912264	shares
CY2021Q3	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	29912264	shares
CY2021	prct	Temporary Equity Dividends TemporaryEquityDividends	0.08
CY2021	prct	Temporary Equity Dividends TemporaryEquityDividends	0.08
CY2021	prct	Temporary Equity Dividends TemporaryEquityDividends	0.08
CY2021Q4	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	0	USD
CY2020Q4	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	0	USD
CY2021Q4	prct	Temporary Equity Voting Rights Number Of Votes Per Share Of Common Stock If Converted TemporaryEquityVotingRightsNumberOfVotesPerShareOfCommonStockIfConverted	1	customer
CY2021Q3	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	29912264	shares
CY2021Q3	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	29912264	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	64300000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	125700000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	10900000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2000000	USD
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	3400000	USD
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1600000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.10
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y9M18D
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	2700000	USD
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	2900000	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3796000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2173000	USD
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	10600000	USD
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y9M18D
CY2021Q4	prct	Operating Lease Liability And Long Term Debt Maturity Gross OperatingLeaseLiabilityAndLongTermDebtMaturityGross	54500000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4537000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	USD
CY2021Q4	prct	Operating Lease Liability And Long Term Debt Maturity Year One OperatingLeaseLiabilityAndLongTermDebtMaturityYearOne	2445000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2092000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2445000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	12500000	USD
CY2021Q4	prct	Operating Lease Liability And Long Term Debt Maturity Year Two OperatingLeaseLiabilityAndLongTermDebtMaturityYearTwo	14592000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	0	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	37500000	USD
CY2021Q4	prct	Operating Lease Liability And Long Term Debt Maturity Year Three OperatingLeaseLiabilityAndLongTermDebtMaturityYearThree	37500000	USD
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	50000000	USD
CY2021Q4	prct	Operating Lease Liability And Long Term Debt Maturity Gross OperatingLeaseLiabilityAndLongTermDebtMaturityGross	54537000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	441000	USD
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	4000	USD
CY2021Q4	prct	Operating Lease Liability And Long Term Debt Maturity Unamortized Debt Discount OperatingLeaseLiabilityAndLongTermDebtMaturityUnamortizedDebtDiscount	437000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4096000	USD
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	50004000	USD
CY2021Q4	prct	Operating Lease Liability And Long Term Debt OperatingLeaseLiabilityAndLongTermDebt	54100000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2105000	USD
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2021Q4	prct	Operating Lease Liability And Long Term Debt Current OperatingLeaseLiabilityAndLongTermDebtCurrent	2105000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1991000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	50004000	USD
CY2021Q4	prct	Operating Lease Liability And Long Term Debt Excluding Current Maturities OperatingLeaseLiabilityAndLongTermDebtExcludingCurrentMaturities	51995000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.02
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.01
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.23
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.22
CY2020Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	303000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	52832000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	42331000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	555000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	5209000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3830000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	717000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	490000	USD
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	6268000	USD
CY2020Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	3109000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	909000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	511000	USD
CY2021Q4	prct	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	1003000	USD
CY2020Q4	prct	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	1461000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	1418000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	1144000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	68911000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	53179000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	68046000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	52005000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	865000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1174000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	865000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1174000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	865000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1174000	USD
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	16000000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1407000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	986000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	510000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	421000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1917000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1407000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1900000	USD

Files In Submission

Name	View Source	Status
0001628280-22-006885-index-headers.html	Edgar Link	pending
0001628280-22-006885-index.html	Edgar Link	pending
0001628280-22-006885.txt	Edgar Link	pending
0001628280-22-006885-xbrl.zip	Edgar Link	pending
exhibit41-descriptionofcap.htm	Edgar Link	pending
ex_60567517xv4xoxford-proc.htm	Edgar Link	pending
ex_divcoleasewithproceptbi.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_0.jpg	Edgar Link	pending
image_1.jpg	Edgar Link	pending
image_11.jpg	Edgar Link	pending
image_12.jpg	Edgar Link	pending
image_13.jpg	Edgar Link	pending
image_14.jpg	Edgar Link	pending
image_2.jpg	Edgar Link	pending
image_20.jpg	Edgar Link	pending
image_22.jpg	Edgar Link	pending
image_23.jpg	Edgar Link	pending
image_25.jpg	Edgar Link	pending
image_27.jpg	Edgar Link	pending
image_28.jpg	Edgar Link	pending
image_29.jpg	Edgar Link	pending
image_3.jpg	Edgar Link	pending
image_30.jpg	Edgar Link	pending
image_31.jpg	Edgar Link	pending
image_32.jpg	Edgar Link	pending
image_33.jpg	Edgar Link	pending
image_34.jpg	Edgar Link	pending
image_35.jpg	Edgar Link	pending
image_36.jpg	Edgar Link	pending
image_37.jpg	Edgar Link	pending
image_38.jpg	Edgar Link	pending
image_39.jpg	Edgar Link	pending
image_4.jpg	Edgar Link	pending
image_5.jpg	Edgar Link	pending
image_6.jpg	Edgar Link	pending
image_8.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
prct-20211231.htm	Edgar Link	pending
prct-20211231.xsd	Edgar Link	pending
prct-20211231_cal.xml	Edgar Link	unprocessable
prct-20211231_def.xml	Edgar Link	unprocessable
prct-20211231_g1.jpg	Edgar Link	pending
prct-20211231_g10.jpg	Edgar Link	pending
prct-20211231_g11.jpg	Edgar Link	pending
prct-20211231_g2.jpg	Edgar Link	pending
prct-20211231_g3.jpg	Edgar Link	pending
prct-20211231_g4.jpg	Edgar Link	pending
prct-20211231_g5.jpg	Edgar Link	pending
prct-20211231_g6.jpg	Edgar Link	pending
prct-20211231_g7.jpg	Edgar Link	pending
prct-20211231_g8.jpg	Edgar Link	pending
prct-20211231_g9.jpg	Edgar Link	pending
prct-20211231_htm.xml	Edgar Link	completed
prct-20211231_lab.xml	Edgar Link	unprocessable
prct-20211231_pre.xml	Edgar Link	unprocessable
prct-ex311soxcertification.htm	Edgar Link	pending
prct-ex312soxcertification.htm	Edgar Link	pending
prct-ex321soxcertification.htm	Edgar Link	pending
prct-ex322soxcertification.htm	Edgar Link	pending
pwc_prctconsentfy2110-k.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PRCT
PROCEPT BioRobotics Corp Stock $prct

2021 Q4 Form 10-K Financial Statement

#000162828022006885 Filed on March 22, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRCT PROCEPT BioRobotics Corp Stock $prct

2021 Q4 Form 10-K Financial Statement

#000162828022006885 Filed on March 22, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRCT
PROCEPT BioRobotics Corp Stock $prct